New cancer drug enters first human trials for Tough-to-Treat tumors
NCT ID NCT05174637
Summary
This is a first-in-human, early-stage study to test the safety and find the right dose of a new experimental drug called FDA018-ADC in people with advanced solid tumors that have spread. The main goals are to see what side effects occur, how the drug moves through the body, and if it shows any early signs of shrinking tumors. The study will enroll about 78 adults with various advanced cancers who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.